McKinsey & Company’s Conduct and Conflicts at the Heart of the Opioid Epidemic
On Wednesday, April 27, 2022, at 10:00 a.m. ET, Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, will hold a hearing to examine the key role played by McKinsey in the opioid epidemic, a public health crisis that has killed half a million Americans and continues to claim tens of thousands of lives every year.
The hearing will examine the findings of the Committee’s interim staff report that revealed McKinsey consultants frequently worked on Food and Drug Administration (FDA) contracts while also working for opioid manufacturers such as Purdue Pharma, and failed to disclose these conflicts of interest to the FDA—in apparent violation of contract requirements and federal law. The report also highlighted evidence that McKinsey used its government consulting work to solicit more business from opioid manufacturers and tried to influence government officials, including the Trump Administration’s Secretary of Health and Human Services Alex Azar, to advance the interests of its private sector opioid clients.
The Committee’s investigation aims to uncover the full scope of McKinsey’s conflicts of interest and other abusive practices in order to strengthen federal contracting laws and increase transparency in consulting projects for the federal government. To date, McKinsey has failed to fully cooperate with the Committee’s investigation and has refused to provide basic information about certain clients and the work McKinsey did for them.
Commonwealth of Massachusetts
In Joint Testimony with
Senior Enforcement Counsel
Massachusetts Attorney General’s Office
Global Managing Partner
McKinsey & Company
Assistant Dean for Government Procurement Law Studies
George Washington University Law School
Chair, Regulatory Defense, Compliance & White Collar Practice Group
Michael Best & Friedrich LLP